Similarity and consistency assessment of three major online drug–drug interaction resources
Open Access
- 12 April 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4067-4079
Abstract
Aims: The aim of this study was to explore the level of agreement on drug–drug interaction (DDI) information listed in three major online drug information resources (DIRs) in terms of: (1) interacting drug pairs; (2) severity rating; (3) evidence rating; and (4) clinical management recommendations.Methods: We extracted information from the British National Formulary (BNF), Thesaurus and Micromedex. Following drug name normalisation, we estimated the overlap of the DIRs in terms of DDI. We annotated clinical management recommendations either manually, where possible, or through application of a machine learning algorithm.Results: The DIRs contained 51 481 (BNF), 38 037 (Thesaurus) and 65 446 (Micromedex) drug pairs involved in DDIs. The number of common DDIs across the three DIRs was 6970 (13.54% of BNF, 18.32% of Thesaurus and 10.65% of Micromedex). Micromedex and Thesaurus overall showed higher levels of similarity in their severity ratings, while the BNF agreed more with Micromedex on the critical severity ratings and with Thesaurus on the least significant ones. Evidence rating agreement between BNF and Micromedex was generally poor. Variation in clinical management recommendations was also identified, with some categories (i.e., Monitor and Adjust dose) showing higher levels of agreement compared to others (i.e., Use with caution, Wash‐out, Modify administration).Conclusions: There is considerable variation in the DDIs included in the examined DIRs, together with variability in categorisation of severity and clinical advice given. DDIs labelled as critical were more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, and there is a need for harmonisation and standardisation.Keywords
All Related Versions
Funding Information
- Engineering and Physical Sciences Research Council (EP/R51231X/1)
- AstraZeneca
This publication has 25 references indexed in Scilit:
- High-priority drug–drug interactions for use in electronic health recordsJournal of the American Medical Informatics Association, 2012
- Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactionsExpert Opinion on Drug Safety, 2011
- Normalized names for clinical drugs: RxNorm at 6 yearsJournal of the American Medical Informatics Association, 2011
- Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular ToxicitiesThe Oncologist, 2011
- Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening ProgramsAnnals of Pharmacotherapy, 2010
- A brief insight into the BNFPrescriber, 2008
- Evaluation of frequently used drug interaction screening programsPharmacy World & Science, 2008
- Comparative assessment of four drug interaction compendiaBritish Journal of Clinical Pharmacology, 2006
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003